Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Liang Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1893-1965; OpenAlex author ID A5100420716. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. Last author DOI 10.1016/j.mcp.2025.102030↗
  2. Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. Last author DOI 10.1080/21691401.2023.2264358↗
  3. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. First author DOI 10.1016/j.jpha.2021.07.001↗
  4. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Last author DOI 10.1038/s41467-022-33037-x↗
  5. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibito… Co-author DOI 10.3892/or.2020.7468↗
  6. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic… Co-author DOI 10.1002/cam4.1974↗
  7. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Co-author DOI 10.1097/fpc.0000000000000241↗
  8. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. Co-author DOI 10.1007/s00432-014-1728-x↗
  9. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0070216↗
  10. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Co-author DOI 10.1158/1078-0432.ccr-11-1387↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong-Juan Yao · 4 shared papers, 2019–2025 · strength 0.59
  2. Yuchen Shi · 3 shared papers, 2022–2025 · strength 0.49
  3. Hebing Chen · 3 shared papers, 2022–2025 · strength 0.49
  4. Yong‐Su Zhen · 2 shared papers, 2020–2022 · strength 0.31
  5. Xiaofei Zhou · 2 shared papers, 2022–2023 · strength 0.29
  6. Rong‐Guang Shao · 2 shared papers, 2019–2022 · strength 0.23
  7. Rui Cao · 2 shared papers, 2019–2022 · strength 0.23
  8. Qifeng Xiao · 1 shared paper, 2025 · strength 0.20
  9. Chenyu Yuan · 1 shared paper, 2025 · strength 0.20
  10. Xiaohong Liu · 1 shared paper, 2025 · strength 0.20
  11. Qingfang Miao · 1 shared paper, 2022 · strength 0.17
  12. Yangyang Wang · 1 shared paper, 2022 · strength 0.17
  13. Xiaohong Liu · 1 shared paper, 2023 · strength 0.16
  14. Weijin Sheng · 1 shared paper, 2020 · strength 0.13
  15. Yi Li · 1 shared paper, 2022 · strength 0.13
  16. Li Zhang · 1 shared paper, 2022 · strength 0.13
  17. Liewei Wang · 3 shared papers, 2012–2016 · strength 0.11
  18. Brooke L. Fridley · 2 shared papers, 2013–2016 · strength 0.09
  19. Gloria M. Petersen · 2 shared papers, 2013–2016 · strength 0.09
  20. Jianwei Zhang · 1 shared paper, 2016 · strength 0.06
  21. Robert R. McWilliams · 1 shared paper, 2016 · strength 0.06
  22. Ren-bao Yang · 1 shared paper, 2014 · strength 0.05
  23. YouQian Zhang · 1 shared paper, 2014 · strength 0.05
  24. Jiong Chen · 1 shared paper, 2014 · strength 0.05
  25. Katarzyna A. Ellsworth · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.